Table 1 Expression and localization of EGFR, IL-6, and PAI-1 in formalin-fixed, paraffin embedded EOC samples evaluated by IHC

EOC sample ^a	EGFR		IL-6	PAI-1
	M	C	C	C
1		+/++^b	−	+
2	++		+	+
3	+		+	+
4	++		+	++
5	+	++	+	++
6	++	++	+	+
7	+++	+++	+++	+++
8	++		++	+
9		+	−	−
10	+	+	+	+
11		++	++	++
12	++		+	++
13		++	−	+
14	++	++	−	−
15	++	+	+	+
16		+/++	−	+
17	+++		−	−
18		+++	+	++
19	+++		−	++
20	+++	+++	+	++
21	++	+++	+	++
22	+++	+++	+++	+++
23	+	+	+	+

Abbreviations: C, cytoplasmic staining; EGFR, epidermal growth factor receptor; EOC, epithelial ovarian cancer; IHC, immunohistochemistry; M, membrane staining, PAI, plasminogen activator inhibitor.
^aThe characteristics of EOC patients are reported in Supplementary Table 1. The numbers in bold italics highlight patients whose ascites co-expressed detectable levels of IL-6 and PAI-1 (see Figure 6b).
^bArbitrary scores were given by two independent observers: negative (−), faint (+), moderate (++), and strong (+++) staining.

Quick links

Search